Retatrutide, a innovative dual-acting glucose-dependent incretin mimetic, represents a significant leap in peptide medicines for the handling of type 2 diabetes and, increasingly, obesity. Unlike many existing therapeutic interventions, retatrutide integrates the actions of a GLP-1 receptor agonist and a GIP receptor agonist, offering a more holist